STOCK TITAN
  1. Home
  2. Sec-filings
  3. SLXN
  4. [Form 4] Silexion Therapeutics Corp Insider Trading Activity

Silexion Therapeutics (SLXN) director granted 7,576 shares and 8,904 options

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Peled Amnon reported acquisition or exercise transactions in this Form 4 filing.

Silexion Therapeutics Corp director Amnon Peled received equity awards from the company. On February 20, 2026, he was granted 7,576 ordinary shares at no cost through fully vested restricted share units issued for his director services.

On the same date, he was also granted stock options for 8,904 ordinary shares, with the options vesting in full one year after the board’s approval date and expiring ten years after that approval. An additional option holding of 780 shares was reported for informational purposes only, with no transactions effected in that line.

Positive

  • None.

Negative

  • None.
Insider Peled Amnon
Role Director
Type Security Shares Price Value
Grant/Award Stock Option (right to buy Ordinary Shares) 8,904 $0.00 --
Grant/Award Ordinary Shares 7,576 $0.00 --
holding Stock Option (right to buy Ordinary Shares) -- -- --
Holdings After Transaction: Stock Option (right to buy Ordinary Shares) — 8,904 shares (Direct); Ordinary Shares — 8,237 shares (Direct)
Footnotes (1)
  1. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Peled Amnon
(Last) (First) (Middle)
55 NACHMANI ST
(Street)
TEL AVIV L3 6777634
(City) (State) (Zip)
2. Issuer Name and Ticker or Trading Symbol
Silexion Therapeutics Corp [ SLXN ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
X Director 10% Owner
Officer (give title below) Other (specify below)
3. Date of Earliest Transaction (Month/Day/Year)
02/20/2026
4. If Amendment, Date of Original Filed (Month/Day/Year)
 6. Individual or Joint/Group Filing (Check Applicable Line)
X Form filed by One Reporting Person
Form filed by More than One Reporting Person
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Ordinary Shares 02/20/2026 A(1) 7,576 A $0 8,237 D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy Ordinary Shares) $1.65 02/20/2026 A(2) 8,904 02/12/2027(3) 02/12/2036(3) Ordinary Shares 8,904 $0 8,904 D
Stock Option (right to buy Ordinary Shares)(4) $18.9 02/09/2026 02/09/2035 Ordinary Shares 780 780 D
Explanation of Responses:
1. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, par value $0.0135 per share, of the Issuer ("ordinary shares"), in respect of the Reporting Person's director services to the Issuer. The grant was approved by the Issuer's board of directors.
2. The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of options to purchase ordinary shares, which grant was approved by the Issuer's board of directors.
3. The options reported in this row vest in their entirety on the one-year anniversary of, and expire on the ten-year anniversary of, the date of approval of their grant by the Issuer's board of directors.
4. There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
/s/ Mirit Horenshtein Hadar, Attorney-in-fact 02/23/2026
** Signature of Reporting Person Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Silexion Therapeutics (SLXN) report for Amnon Peled?

Silexion reported that director Amnon Peled received equity awards, including ordinary shares and stock options, as compensation for his board service. These were structured as a share grant settled from RSUs and a separate option grant approved by the company’s board of directors.

How many Silexion Therapeutics (SLXN) shares did Amnon Peled acquire in this Form 4?

Amnon Peled received 7,576 ordinary shares of Silexion Therapeutics at no cash cost to him. The shares came from fully vested restricted share units that were immediately settled into underlying ordinary shares as compensation for his work as a director.

What stock option grant did Amnon Peled receive from Silexion Therapeutics (SLXN)?

He was granted options to purchase 8,904 ordinary shares of Silexion Therapeutics. These options were approved by the board, vest entirely on the one-year anniversary of their approval date, and expire on the ten-year anniversary of that same approval date.

Were any of Amnon Peled’s Silexion Therapeutics (SLXN) transactions open-market buys or sells?

No open-market buying or selling was reported. The Form 4 describes grants of ordinary shares and stock options approved by the board as compensation, with a transaction code for grant or award, rather than purchases or sales on the open market.

What does the Form 4 say about the additional 780 Silexion Therapeutics (SLXN) options?

The Form 4 notes a holding of options over 780 ordinary shares, but explicitly states there were no transactions in that row. Those options are included only for informational purposes and do not represent a new grant, purchase, or sale.

Why did Silexion Therapeutics (SLXN) grant RSUs and options to director Amnon Peled?

The filing explains that the equity awards compensate Amnon Peled for his director services to Silexion. The RSUs, settled into ordinary shares, and the stock options were each granted pursuant to approvals by the Silexion Therapeutics board of directors.